Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SETBP1 divergent transcript (SETBP1-DT) refers to a non-canonical RNA transcript at the SETBP1 gene locus. Unlike the well-studied protein-coding SETBP1 gene, which encodes a transcription factor involved in gene regulation, development, and cancer biology, SETBP1-DT is not well-characterized in scientific literature. There is insufficient evidence to classify SETBP1-DT as a therapeutic target, and it is not described as a receptor, enzyme, or signaling molecule. Further research is necessary to define its expression, function, and clinical significance if any. Most structural, functional, and disease-related information pertains to the canonical SETBP1 gene rather than the divergent transcript[1][3][4][5].
None
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SETBP1 divergent transcript (SETBP1-DT).